翰宇药业(300199) - 2022 Q3 - 季度财报

Revenue and Profitability - Revenue for Q3 2022 reached ¥174,434,483.66, an increase of 23.23% compared to the same period last year[7] - Net profit attributable to shareholders was -¥48,558,678.78, a decrease of 46.91% year-on-year[7] - Net profit excluding non-recurring gains and losses was -¥76,185,909.91, an increase of 16.37% compared to the previous year[7] - Total operating revenue for the current period reached ¥530,964,140.72, an increase from ¥507,727,212.06 in the previous period, reflecting a growth of approximately 4.9%[45] - The company reported a net loss of ¥943,471,946.57, worsening from a loss of ¥796,690,192.54 in the previous period[43] - The net profit for the current period is -148,227,434.65, compared to -117,633,535.52 in the previous period, indicating a decline of approximately 26%[49] - Operating profit for the current period is -148,712,993.45, compared to -110,557,242.25 in the previous period, reflecting a worsening performance[49] - Total comprehensive income for the current period is -137,350,762.01, compared to -118,786,170.13 in the previous period, showing a decline of about 15%[51] - The basic and diluted earnings per share are both -0.16, compared to -0.13 in the previous period, reflecting a decline in profitability[51] Cash Flow and Liquidity - Cash flow from operating activities showed a net amount of ¥7,976,018.03, down 93.85% year-on-year[7] - The net cash flow from operating activities decreased by 93.85% to ¥7,976,018.03 compared to ¥129,767,232.40 in the same period last year[23] - Cash inflow from operating activities is 581,413,693.87, down from 699,261,065.58 in the previous period, representing a decrease of approximately 17%[53] - The total cash and cash equivalents at the end of the period stood at $49,608,122.89, down from $177,378,071.75, representing a decrease of approximately 72%[56] - The company’s cash and cash equivalents decreased to ¥55,146,336.36 from ¥138,922,817.15 at the beginning of the year[37] - The net increase in cash and cash equivalents was -¥50,899,761.36, a 74.54% improvement from -¥199,938,204.68 in the same period last year[23] Assets and Liabilities - Total assets as of the end of Q3 2022 were ¥3,717,233,449.30, a decrease of 4.84% from the end of the previous year[7] - The total assets decreased to ¥3,717,233,449.30 from ¥3,906,390,317.84, a decline of about 4.8%[43] - Total liabilities decreased to ¥2,193,828,725.82 from ¥2,258,418,141.63, reflecting a reduction of approximately 2.9%[43] - Shareholders' equity attributable to the parent company was ¥1,496,548,242.85, down 5.56% from the end of the previous year[7] - The company's equity attributable to shareholders decreased to ¥1,496,548,242.85 from ¥1,584,661,419.91, a decline of about 5.5%[43] - The long-term borrowings decreased to ¥975,905,375.99 from ¥1,072,274,475.14, a reduction of about 9.0%[43] Research and Development - R&D expenses for the first nine months of 2022 were ¥102,432,535.37, an increase of 47.42% year-on-year[20] - Research and development expenses increased significantly to ¥102,432,535.37, up from ¥69,483,063.11, representing a rise of approximately 47.5%[45] Inventory and Goodwill - The company reported a significant increase in inventory by 40.70% to ¥221,101,092.53 due to increased stocking[18] - The company recorded a 1364.36% increase in goodwill to ¥2,798,778.99, resulting from mergers under different control[18] Financing Activities - Total cash inflow from financing activities decreased by 73.19% to ¥366,002,647.16 from ¥1,365,284,136.16 year-on-year[23] - Cash inflow from financing activities was $366,002,647.16, down from $1,365,284,136.16, indicating a significant reduction in financing cash inflows[56] Regulatory and Business Developments - The company received a registration acceptance notice for the raw material drug liraglutide on July 20, 2022, from the National Medical Products Administration[33] - The company’s subsidiary obtained a processing license for industrial hemp in Yunnan, enhancing its domestic business capabilities[36] - The company initiated a Phase I clinical trial for the HY3000 nasal spray after receiving approval from the National Medical Products Administration on August 24, 2022[36] Other Financial Metrics - The company reported interest expenses of 65,588,610.08, an increase from 52,658,555.46 in the previous period, which is a rise of about 24%[49] - The company recorded a foreign exchange gain of 10,876,672.64, compared to a loss of -1,152,634.61 in the previous period, indicating a significant turnaround[51] - The company incurred credit impairment losses of -11,116,340.66, compared to -6,292,879.85 in the previous period, which is an increase of about 77%[49] - Other income for the current period is 17,833,302.73, down from 39,046,919.65 in the previous period, reflecting a decrease of approximately 54%[49] Audit and Reporting - The company did not undergo an audit for the third quarter report, which may affect the reliability of the financial data presented[58] - The report was issued by the board of directors on October 29, 2022, providing timely insights into the company's financial performance[58]